Fol­low­ing Vounatsos' an­nounced de­par­ture, Bio­gen part­ners with pri­vate Cana­di­an biotech for oral Parkin­son's treat­ment

Bio­gen an­nounced a deal with Cana­di­an biotech Alec­tos Ther­a­peu­tics on Mon­day to de­vel­op a drug aimed at restor­ing lyso­some func­tion, adding an­oth­er can­di­date to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER